Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 4;39(1):195.
doi: 10.1007/s00384-024-04767-9.

Combining moderate dosage of Bevacizumab with TAS-102 provides longer progression-free time in refractory metastatic colorectal Cancer

Kuan-Yu Tseng  1   2   3 , Mu-Ying Yang  3   4 , Wei-Shone Chen  5   3 , Jeng-Kai Jiang  5   3 , Huann-Sheng Wang  5   3 , Shih-Ching Chang  5   3 , Yuan-Tzu Lan  5   3 , Chun-Chi Lin  5   3 , Hung-Hsin Lin  5   3 , Sheng-Chieh Huang  5   3 , Hou-Hsuan Cheng  5   3 , Yi-Wen Yang  5   3 , Yu-Zu Lin  5   3 , Che-Yuan Chang  5   3 , Hao-Wei Teng  6   7
Affiliations

Combining moderate dosage of Bevacizumab with TAS-102 provides longer progression-free time in refractory metastatic colorectal Cancer

Kuan-Yu Tseng et al. Int J Colorectal Dis. .

Abstract

Purpose: We aimed to evaluate the efficacy of moderate doses of bevacizumab in combination with TAS-102 for the treatment of refractory metastatic colorectal cancer.

Methods: A total of 261 patients with refractory mCRC were enrolled and categorized into two groups: TAS-102 combined with bevacizumab and TAS-102 alone. Patients in the bevacizumab combination group were divided into two subgroups based on a median dose of 3.3 mg/kg. Categorical variables were compared using the chi-square or Fisher's exact test, and continuous variables were assessed using the t-test. The Cox proportional hazards model was used to adjust covariates. Survival analysis was performed using the log-rank test and Kaplan-Meier curves. Specific survival was evaluated using restricted mean survival time (RMST) and landmark analysis.

Result: The median progression-free survival (PFS) was 3.7 months in the TAS-102 combined with the bevacizumab group and 2.2 months in the non-bevacizumab group, showing significance in favor of the bevacizumab combination. Median overall survival (OS) was 9.4 months in the bevacizumab combination group and 10.3 months in the group that did not receive combination therapy. A survival benefit was observed within 9.5 months in both the RMST and landmark analyses. The PFS benefit was consistent across different doses of bevacizumab, while no significant difference in OS was observed compared to TAS-102 monotherapy. Both PFS and OS did not significantly differ between the different doses of bevacizumab.

Conclusion: Moderate doses of bevacizumab and TAS-102 provided satisfactory efficacy over the standard dose within a limited timeframe of 9.5 months.

Keywords: Bevacizumab; Chemotherapy; Colorectal cancer; TAS-102.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: This retrospective study was conducted using population-based data from Taipei Veterans General Hospital, Taiwan, following the guidelines of the Declaration of Helsinki. Approval was obtained from the Ethics Committee and Institutional Review Board of Taipei Veterans General Hospital, Taiwan. Due to the retrospective nature of the study, the requirement for written informed consent was waived. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Panel (a) represent the survival curve by using the Kaplan–Meier method to represent the PFS by bevacizumab combination or not (n =261); panel (b) represent the survival curve of the OS by bevacizumab combination or not (n =261); panel (c) represent the specific time in 9.5-month of OS of bevacizumab combination or not in landmark test (n =261); panel (d) illustrates the RMST method for average survival at a specific time of 10 months. Arm1 stands for the bevacizumab combination, and arm2 stands for TAS-102 monotherapy; panel (e) represent the P value of OS as time goes by (n =261)
Fig. 2
Fig. 2
Panel (a) represent the survival curve of PFS by 3 different doses of bevacizumab combination, including none, lower and above medium dose of 3.3mg/kg (n =261); panel (b) represent the OS by 3 different doses of bevacizumab combination, including none, lower and above medium dose of 3.3mg/kg (n =261); panel (c) and (d) analysis among patients using bevacizumab only. Panel (c) represent the PFS in bevacizumab combination group, including lower and above medium dose of 3.3mg/kg (n =86); panel (d) represent the OS in bevacizumab combination group, including lower and above medium dose of 3.3mg/kg (n =86)
See this image and copyright information in PMC

References

    1. Hossain MS, Karuniawati H, Jairoun AA et al (2022) Colorectal cancer: a review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies. Cancers 14:1732. 10.3390/cancers14071732 - PMC - PubMed
    1. Mayer RJ, Van Cutsem E, Falcone A et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372:1909–1919. 10.1056/NEJMoa1414325 - PubMed
    1. Van Cutsem E, Falcone A, Garcia-Carbonero R et al (2017) Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial. ESMO Open 2:e000261. 10.1136/esmoopen-2017-000261 - PMC - PubMed
    1. Prager GW, Taieb J, Fakih M et al (2023) Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med 388:1657–1667. 10.1056/NEJMoa2214963 - PubMed
    1. Cann CG, Cimino S, Grieb B et al (2022) Alternative biweekly dosing schedule of trifluridine-tipiracil (TAS-102) reduces rates of myelosuppression while maintaining therapeutic efficacy in patients (pts) with previously treated metastatic colorectal cancer (mCRC). Am Soc Clin Oncol 40:3559–3559. 10.1200/JCO.2022.40.16_suppl.3559

MeSH terms

LinkOut - more resources